Vaccines targeting <i>ESR1</i> activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer

Published:2024-02-08 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Dailey Gabrielle P.¹,Rabiola Christopher A.¹,Lei Gangjun¹,Wei Junping¹,Yang Xiao-Yi¹,Wang Tao¹,Liu Cong-Xiao¹,Gajda Melissa¹,Hobeika Amy C.¹,Summers Amanda¹,Marek Robert D.¹,Morse Michael A.²,Lyerly Herbert K.¹³⁴,Crosby Erika J.¹⁴,Hartman Zachary C.¹³⁴^ORCID

Affiliation:

1. Department of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USA

2. Department of Medicine, Duke University, Durham, NC, USA

3. Department of Pathology, Duke University, Durham, NC, USA

4. Department of Integrative Immunobiology, Duke University, Durham, NC, USA

Funder

Department of Defense

National Cancer Institute

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2309693

Reference47 articles.

1. Overcoming Endocrine Resistance in Breast Cancer

2. Pathways to Endocrine Therapy Resistance in Breast Cancer

3. The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients

4. Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients

5. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of SUSD3 as a novel prognostic biomarker and therapeutic target for breast cancer;Clinical and Translational Oncology;2024-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3